Neurofilament light antibodies in serum reflect response to natalizumab treatment in MS

Diagnosis, monitoring and biomarkers:
This interesting study investigated if levels of serum antibodies against neurofilament light protein (NF-L) correlate with clinical variants of MS and treatment response in MS. A previous study has demonstrated that increased antibodies to NF-L has been found to reflect neuroinflammatory responses and neurodegeneration in MS. This study included 22 patients with relapsing remitting MS (RRMS), and 26 patients with secondary progressive MS (SPMS).  The autoantibody reactivity to NF-L protein was tested in the serum samples of these individuals. Two other cohorts of RRMS patients on treatment with natalizumab were analysed cross-sectionally in 16 patients and then a group of 24 patients were followed longitudinally.  They found that the NF-L antibodies were higher in MS clinical groups compared to healthy controls. In the MS groups, RRMS had higher NF-L antibodies compared to the SPMS patients. NF-L levels were lower in natalizumab treated patients compared to untreated patients. In the longitudinal cohort, NF-L antibody levels decreased over time, with a significant difference found after 24 months of treatment compared with the baseline measurements. This study gives an indication that monitoring the content of antibodies against the NF-L chain could potentially be used as a predictive biomarker of treatment response in MS.

Amor S, van der Star BJ
Source: Mult Scler. 2014 Feb 10. [Epub ahead of print]
Read the abstract


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial